Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
- 作者: Ibragimov E1, Abdurakhmanov D1, Rozina T1,2, Nikulkina E1, Tanaschuk E1, Odintsov A1, Panevkina S1, Moiseev S1,2
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
- M.V. Lomonosov Moscow State University
- 期: 卷 91, 编号 2 (2019)
- 页面: 40-47
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32918
- DOI: https://doi.org/10.26442/00403660.2019.02.000073
- ID: 32918
如何引用文章
全文:
详细
Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, р<0.0001) and reduction in the number of patients with advanced fibrosis (from 48.1% to 13.8%, р<0.0001). Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases. Conclusion. Entecavir and tenofovir might be recommended for the treatment of chronic hepatitis B because of having potent antiviral effect, high genetic barriers against resistance and good safety.
作者简介
E Ibragimov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
编辑信件的主要联系方式.
Email: info@conmed.ru
аспирант, каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
Moscow, RussiaD Abdurakhmanov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: abdjamal@mail.ru
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
Moscow, RussiaT Rozina
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); M.V. Lomonosov Moscow State University
Email: info@conmed.ru
к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова», факультет фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»
Moscow, RussiaE Nikulkina
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: info@conmed.ru
ассистент, каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
Moscow, RussiaE Tanaschuk
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: info@conmed.ru
к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
Moscow, RussiaA Odintsov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: info@conmed.ru
врач, клиника ревматологии, нефрологии и профпатологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
Moscow, RussiaS Panevkina
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: info@conmed.ru
студентка ФГБОУ ВО «МГУ им. М.В. Ломоносова»
Moscow, RussiaS Moiseev
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); M.V. Lomonosov Moscow State University
Email: info@conmed.ru
проф., зав. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова», факультет фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»
Moscow, Russia参考
- World Health Organization. Global hepatitis report 2017; April 21, 2017; Geneva. Available from: at: http://apps.who.int/iris/bitstream/ handle/10665/255016/9789241565455-eng.pdf?sequence=1&isAllowed=y (Accessed September 15, 2018).
- World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: March 2015; March 12, 2015; Geneva. Available at: http://apps.who.int/iris/bitstream/handle/10665/154590/?sequence=1 (Accessed September 15, 2018).
- Абдурахманов Д.Т., Отрашевская A.В. Энтекавир в лечении хронического гепатита В: многоцентровые рандомизированные исследования и реальная клиническая практика. Терапевтический архив. 2014;86(11):100-4.
- Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты: клиника, диагностика, лечение. М.: ГЭОТАР-Медиа, 2014.
- Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Шестакова И.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Диагностика и лечение гепатита В у взрослых: консенсус экспертов. Инфекционные болезни: Новости. Мнения. Обучение. 2013;4(5):75-102.
- Абдурахманов Д.Т., Моисеев С.В. Выбор аналога нуклеоз(т)идов для лечения хронического гепатита В. Клиническая фармакология и терапия. 2014;23(1):10-6.
- European Association for The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021
- Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Маев И.В., Павлов Ч.С., Федосьина Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Лапина Т.Л., Трухманов А.С., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(3):58-88.
- European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001
- Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non - invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242-7. doi: 10.1111/j.1478-3231.2008.01802.x
- Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide - naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472
- Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long - term continuous entecavir therapy in nucleos(t)ide - naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037
- Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty J.F, Martins E.B, Charuworn P, Kitrinos K.M, Subramanian G.M, Gane E, Marcellin P. Seven - year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-64. doi: 10.1007/s10620-014-3486-7
- Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis G.V, Margariti A, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Viganò M, Rumi M.G, Vinci M, Belli L.S, Cologni G, Rizzi M, Milanese M, Strazzabosco M, Minola E, Giorgini A.M, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Colombo A.E, Bellati G, Angeli E, Gubertini G.A, Rizzardini G, Fasano M, Santantonio T, Terreni N.M, Spinzi G, Facchetti F, Invernizzi F, Mangia G, Colombo M. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Dig Liv Dis. 2014;46(suppl 1):e14. doi: 10.1016/j.dld.2014.01.033
- Мамонова Н.А., Сухарева Г.В., Чуланов В.П., Карандашова И.В., Лебедева Е.Б., Пименов Н.Н. Эффективность энтекавира у ламивудин - рефрактерных больных хроническим гепатитом В при раннем переключении с ламивудина на энтекавир: предварительный анализ результатов трехлетнего исследования. Инфекционные болезни. 2014;12(1):81-6.
- Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, Tanwandee T. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2017;47(3):E161-E168. doi: 10.1111/hepr.12743
- Köklü S, Tuna Y, Gülşen M.T, Demir M, Köksal A.Ş, Koçkar M.C, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Long - term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus - related cirrhosis. Clin Gastroenterol Hepatol. 2013;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003
- Park J.W, Kwak K.M, Kim S.E, Jang M.K, Suk K.T, Kim D.J, Park S.H, Lee M.S, Kim H.S, Park C.K. Comparison of the long - term efficacy between entecavir and tenofovir in treatment - naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17(1):39. doi: 10.1186/s12876-017-0596-7
- Wang Y, Thongsawat S, Gane E.J, Liaw Y.F, Jia J, Hou J, Chan H.L, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov N.V. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37-46. doi: 10.1111/jvh.12025
- Pan H.Y, Pan H.Y, Song W.Y, Zheng W, Tong Y.X, Yang D.H, Dai Y.N, Chen M.J, Wang M.S, Huang Y.C, Zhang J.J, Huang H.J. Long - term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat. 2017;24(suppl 1):29-35. doi: 10.1111/jvh.12794
- Tsai M.C, Chen C.H, Hung C.H, Lee C.M, Chiu K.W, Wang J.H, Lu S.N, Tseng P.L, Chang K.C, Yen Y.H, Hu T.H. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match - control study. Clin Microbiol Infect. 2014;20(2):O90-O100. doi: 10.1111/1469-0691.12220
- Ефремова О.С., Кожевникова Г.М., Вознесенский С.Л., Аликеева Г.К. Эффективность современных нуклеозидных аналогов в лечении больных HbeAg - негативным хроническим гепатитом В. Инфекционные болезни. 2013;11(4):5-11.
- Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment - naïve patients with chronic hepatitis B: a multicenter real - life study. Int J Infect Dis. 2014;28:153-9. doi: 10.1016/j.ijid.2014.09.004
- Idilman R, Gunsar F, Koruk M, Keskin O, Meral C.E, Gulsen M, Elhan A.H, Akarca U.S, Yurdaydin C. Long - term entecavir or tenofovir disoproxil fumarate therapy in treatment - naïve chronic hepatitis B patients in the real - world setting. J Viral Hepat. 2015;22(5):504-10. doi: 10.1111/jvh.12358
- Kayaaslan B, Akinci E, Ari A, Tufan Z.K, Alpat S.N, Gunal O, Tosun S, Guner R, Tabak F. A long - term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue - naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol. 2018;42(1):40-7. doi: 10.1016/j.clinre.2017.06.008
- Osborn M.K. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2009;5:789-98. doi: 10.2147/tcrm.s5318
- Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine - based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283-92. doi: 10.1002/hep.26885
- Wang J, Du L.Y, Zhu X, Chen E.Q, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Ind J Med Microbiol. 2015;33(5):20-5. doi: 10.4103/0255-0857.148827
- Tsai M.C, Chen C.H, Tseng P.L, Hung C.H, Chiu K.W, Wang J.H, Lu S.N, Lee C.M, Chang K.C, Yen Y.H, Lin M.T, Chou Y.P, Hu T.H. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95. doi: 10.1016/j.cmi.2015.05.035
- Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I.M, Washington M.K, Germanidis G, Flaherty J.F, Aguilar Schall R, Bornstein J.D, Kitrinos K.M, Subramanian G.M, Mc Hutchison J.G, Heathcote E.J. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open - label follow - up study. Lancet. 2013;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
- Chang T.T, Liaw Y.F, Wu S.S, Schiff E, Han K.H, Lai C.L, Safadi R, Lee S.S, Halota W, Goodman Z, Chi Y.C, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long - term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. doi: 10.1002/hep.23785
- Wang J.L, Du X.F, Chen S.L, Yu Y.Q, Wang J, Hu X.Q, Shao L.Y, Chen J.Z, Weng X.H, Zhang W.H. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine - based therapy. World J Gastroenterol: WJG. 2015;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598
- Чуланов В.П. Резистентность к противовирусным препаратам при хроническом гепатите В. Фарматека. 2010;(4):20-6.
- Абдурахманов Д.Т., Моисеев С.В. Безопасность длительной терапии тенофовиром у больных хроническим гепатитом B. Клиническая фармакология и терапия. 2014;23(2):20-5.
- Kim S.S, Hwang J.C, Lim S.G, Ahn S.J, Cheong J.Y, Cho S.W. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223-33. doi: 10.1038/ajg.2014.145
- Choi J.W, Kim S.H, Seo J.H, Cho Y.S, Won S.Y, Park B.K, Jeon H.H, Lee Y.K, Lee C.K. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J. 2018;59(3):383-8. doi: 10.3349/ymj.2018.59.3.383
- Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, Chotiyaputta W, Nimanong S. Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real - world clinical Practice: 968. Hepatology. 2013;58:672A. doi: 10.1002/hep.26856
- Marcellin P, Gane E.J, Flisiak R, Trinh H.N, Petersen J, Gure S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:313A-314A. doi: 10.1002/hep.27486